<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="milroy" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">gene</book-id>
    <book-title-group>
      <book-title>GeneReviews<sup>&#x000ae;</sup></book-title>
    </book-title-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Adam</surname>
          <given-names>Margaret P</given-names>
        </name>
        <role>Editor-in-Chief</role>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ardinger</surname>
          <given-names>Holly H</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Pagon</surname>
          <given-names>Roberta A</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Wallace</surname>
          <given-names>Stephanie E</given-names>
        </name>
      </contrib>
      <role>Senior Editors</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Bean</surname>
          <given-names>Lora JH</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Mefford</surname>
          <given-names>Heather C</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Stephens</surname>
          <given-names>Karen</given-names>
        </name>
      </contrib>
      <role>Molecular Genetics</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Amemiya</surname>
          <given-names>Anne</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ledbetter</surname>
          <given-names>Nikki</given-names>
        </name>
      </contrib>
      <role>Genetic Counseling</role>
    </contrib-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>1993</year>
    </pub-date>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>2017</year>
    </pub-date>
    <issn>2372-0697</issn>
    <publisher>
      <publisher-name>University of Washington, Seattle</publisher-name>
      <publisher-loc>Seattle (WA)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 1993-2017, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.</copyright-statement>
      <copyright-year>2017</copyright-year>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK138602/">
        <license-p>GeneReviews&#x000ae; chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (<ext-link ext-link-type="uri" xlink:href="http://www.genereviews.org/">http://www.genereviews.org/</ext-link>) and copyright (&#x000a9; 1993-2017 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.</license-p>
        <license-p>For more information, see the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>.</license-p>
        <license-p>For questions regarding permissions or whether a specified use is allowed, contact: <email>admasst@uw.edu</email>.</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Genetics</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Medicine</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Diseases</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="ednotes">
      <p content-type="genetic_counseling">
<italic toggle="yes">Genetic counseling is the process of
providing individuals and families with information on the nature, inheritance,
and implications of genetic disorders to help them make informed medical and
personal decisions. The following section deals with genetic risk assessment and
the use of family history and genetic testing to clarify genetic status for
family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with
a genetics professional</italic>. &#x02014;ED.</p>
      <p content-type="resources">
<italic toggle="yes">GeneReviews staff has selected the following disease-specific and/or
umbrella support organizations and/or registries for the benefit of individuals
with this disorder and their families. GeneReviews is not responsible for the
information provided by other organizations. For information on selection
criteria, click <related-object source-id="gene" document-id="app4">here</related-object>.</italic></p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">milroy</book-part-id>
      <title-group>
        <title>Milroy Disease</title>
        <alt-title alt-title-type="alt-title">Synonyms: Hereditary Lymphedema, Type I; Milroy Congenital Lymphedema</alt-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="no">
          <name name-style="western">
            <surname>Brice</surname>
            <given-names>Glen W</given-names>
          </name>
          <xref ref-type="aff" rid="milroy.AFF1"/>
          <degrees>RGN BSc (Hons)</degrees>
          <email>gbrice@sgul.ac.uk</email>
        </contrib>
        <contrib contrib-type="author" corresp="no">
          <name name-style="western">
            <surname>Mansour</surname>
            <given-names>Sahar</given-names>
          </name>
          <xref ref-type="aff" rid="milroy.AFF2"/>
          <degrees>FRCP</degrees>
          <email>smansour@sgul.ac.uk</email>
        </contrib>
        <contrib contrib-type="author" corresp="no">
          <name name-style="western">
            <surname>Ostergaard</surname>
            <given-names>Pia</given-names>
          </name>
          <xref ref-type="aff" rid="milroy.AFF3"/>
          <degrees>PhD</degrees>
          <email>posterga@sgul.ac.uk</email>
        </contrib>
        <contrib contrib-type="author" corresp="no">
          <name name-style="western">
            <surname>Connell</surname>
            <given-names>Fiona</given-names>
          </name>
          <xref ref-type="aff" rid="milroy.AFF4"/>
          <degrees>MBChB, MRCPCH, MD</degrees>
          <email>fiona.connell@gstt.co.uk</email>
        </contrib>
        <contrib contrib-type="author" corresp="no">
          <name name-style="western">
            <surname>Jeffery</surname>
            <given-names>Steve</given-names>
          </name>
          <xref ref-type="aff" rid="milroy.AFF5"/>
          <degrees>PhD</degrees>
          <email>sggt100@sgul.ac.uk</email>
        </contrib>
        <contrib contrib-type="author" corresp="no">
          <name name-style="western">
            <surname>Mortimer</surname>
            <given-names>Peter</given-names>
          </name>
          <xref ref-type="aff" rid="milroy.AFF6"/>
          <degrees>MD, FRCP</degrees>
          <email>mortimer@sgul.ac.uk</email>
        </contrib>
      </contrib-group>
      <aff id="milroy.AFF1">SW Thames Regional Genetics Department <break/>St George's, University of London<break/>London, United Kingdom</aff>
      <aff id="milroy.AFF2">Consultant Geneticist, SW Thames Regional Genetics Department <break/>St George's, University of London </aff>
      <aff id="milroy.AFF3">Medical Genetics Unit, Clinical Developmental Sciences<break/>St George's, University of London<break/>London, United Kingdom</aff>
      <aff id="milroy.AFF4">Guy&#x02019;s Genetics Service<break/>Guy&#x02019;s Hospital<break/>London, United Kingdom</aff>
      <aff id="milroy.AFF5">Medical Genetics Unit, Clinical Developmental Sciences<break/>St George's, University of London<break/>London, United Kingdom</aff>
      <aff id="milroy.AFF6">Department of Cardiac and Vascular Sciences (Dermatology) <break/>St George's, University of London<break/>London, United Kingdom</aff>
      <pub-history>
        <date iso-8601-date="2006-04-27" date-type="created">
          <day>27</day>
          <month>04</month>
          <year>2006</year>
        </date>
        <date iso-8601-date="2014-09-25" date-type="updated">
          <day>25</day>
          <month>09</month>
          <year>2014</year>
        </date>
        <date iso-8601-date="2007-04-06" date-type="revised">
          <day>06</day>
          <month>04</month>
          <year>2007</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="gene">GeneReviews<sup>&#x000ae;</sup></related-object>
      <related-object link-type="previous-part-link" source-id="gene" document-id="anophthalmia-ov" document-type="chapter">Microphthalmia/Anophthalmia/Coloboma Spectrum</related-object>
      <related-object link-type="next-part-link" source-id="gene" document-id="kss" document-type="chapter">Mitochondrial DNA Deletion Syndromes</related-object>
      <abstract id="milroy.Summary">
        <title>Summary</title>
        <sec>
          <title>Clinical characteristics</title>
          <p>Milroy disease is characterized by lower-limb lymphedema, present as pedal edema at (or before) birth or developing soon after. Occasionally it develops later in life. The severity of edema shows both inter- and intrafamilial variability. Swelling is usually bilateral but can be asymmetric. The degree of edema can progress but in some instances can improve, particularly in early years. Other features sometimes associated with Milroy disease include hydrocele (37% of males), prominent veins (23%), upslanting toenails (14%), papillomatosis (10%), and urethral abnormalities in males (4%). Cellulitis, which can damage the lymphatic vessels, occurs in approximately 20% of affected individuals, with infection significantly more likely in males than females. </p>
        </sec>
        <sec>
          <title>Diagnosis/testing</title>
          <p>Milroy disease is diagnosed by clinical findings and confirmed by molecular genetic testing. Lymphoscintigraphy can be performed; the characteristic finding is lack of uptake of radioactive colloid in the ilioinguinal lymph nodes caused by a paucity of lymphatic vessels or abnormal function of the vessels in the lower limbs. <italic toggle="yes">FLT4 (VEGFR3</italic>) is the only gene known to be associated with Milroy disease.</p>
        </sec>
        <sec>
          <title>Management</title>
          <p><italic toggle="yes">Treatment of manifestations:</italic> A lymphedema therapist may utilize fitted stockings and massage to improve the cosmetic appearance or decrease the size of the limb and reduce the risk of complications. Improvement in swelling is usually possible with use of properly fitted compression hosiery and/or bandaging and well-fitting, supportive shoes. Toe gloves may be of benefit and good skin care is essential.</p>
          <p><italic toggle="yes">Prevention of secondary complications:</italic> Frequency of cellulitis can be reduced through good skin hygiene, prompt treatment of infections with antibiotics, and prophylactic antibiotics for recurrent episodes. </p>
          <p><italic toggle="yes">Agents/circumstances to avoid</italic>: Wounds to limbs; long periods of immobility with the legs in a dependent position; and medications that can cause increased leg swelling. </p>
          <p><italic toggle="yes">Evaluation of relatives at risk</italic>: Evaluating relatives at risk ensures identification of those who will benefit from treatment early in the disease course.</p>
        </sec>
        <sec>
          <title>Genetic counseling</title>
          <p>Milroy disease is inherited in an autosomal dominant manner. Each child of an individual with Milroy disease has a 50% chance of inheriting the pathogenic variant. Although <italic toggle="yes">de novo</italic> mutation has been reported, the proportion of cases caused by <italic toggle="yes">de novo</italic> mutation is not known. Ultrasonography during pregnancy may detect swelling of the dorsum of the feet, mild pleural effusions which often resolve and (very rarely) more extensive edematous states (hydrops fetalis) in an affected fetus. Prenatal testing is possible for pregnancies at increased risk if the pathogenic variant in the family is known; however, it is rarely requested.</p>
        </sec>
      </abstract>
    </book-part-meta>
    <body>
      <sec id="milroy.Diagnosis">
        <title>Diagnosis</title>
        <sec id="milroy.Suggestive_Findings">
          <title>Suggestive Findings</title>
          <p>Milroy disease should be suspected in individuals with:</p>
          <list list-type="bullet">
            <list-item>
              <p>Lower-limb swelling that is:</p>
              <list list-type="bullet">
                <list-item>
                  <p>Usually but not always bilateral;</p>
                </list-item>
                <list-item>
                  <p>Present at birth or develops soon after.Note: In neonates the swelling predominantly affects the dorsum of the feet; with age, the swelling may improve or progress to affect the whole lower leg.</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>Large-caliber veins;</p>
            </list-item>
            <list-item>
              <p>Upslanting, &#x02018;ski-jump&#x02019; toenails.</p>
            </list-item>
          </list>
          <p>Evaluation of the limb swelling can include lymphoscintigraphy. Radioactive colloid is injected into the toe web spaces and uptake in the ilioinguinal nodes is measured at intervals. Lymphoscintigraphy is performed to determine if there is lack of uptake of radioactive tracer. This can help with the diagnosis of Milroy disease as other forms of lymphedema can have differing patterns on lymphoscintigraphy [<xref ref-type="bibr" rid="milroy.REF.connell.2013.303">Connell et al 2013</xref>]. In cases of unilateral swelling, lymphoscintigraphy can determine if lymphatic drainage is impaired in the 'unaffected' leg. </p>
          <p>Note: (1) Lymphoscintigraphy normally replaces lymphangiography (x-ray after direct injection of dye into the lymphatic vessels in the foot) as it is less invasive. (2) Lymphangiography is also technically more problematic because of difficulties locating lymphatic vessels for cannulation.</p>
          <p>Lymphoscintigraphy is not essential to make the diagnosis and one can proceed directly to molecular testing. </p>
        </sec>
        <sec id="milroy.Establishing_the_Diagnosis">
          <title>Establishing the Diagnosis</title>
          <p>The diagnosis of Milroy disease is established in a proband with identification of a pathogenic variant in <italic toggle="yes">FLT4</italic> (<italic toggle="yes">VEGFR3</italic>), the only gene known to be associated with Milroy disease [<xref ref-type="bibr" rid="milroy.REF.ferrell.1998.2073">Ferrell et al 1998</xref>, <xref ref-type="bibr" rid="milroy.REF.irrthum.2000.295">Irrthum et al 2000</xref>, <xref ref-type="bibr" rid="milroy.REF.karkkainen.2000a.153">Karkkainen et al 2000a</xref>, <xref ref-type="bibr" rid="milroy.REF.evans.2003.697">Evans et al 2003</xref>] (see <xref ref-type="table" rid="milroy.T.summary_of_molecular_genetic_te">Table 1</xref>). </p>
          <p><bold>One genetic testing strategy</bold> is molecular genetic testing of <italic toggle="yes">FLT4</italic> by sequence analysis of exons 17 to 26. </p>
          <p><bold>An alternative genetic testing strategy</bold> is use of a multi-gene panel that includes <italic toggle="yes">FLT4</italic> and other genes of interest (see <xref ref-type="sec" rid="milroy.Differential_Diagnosis">Differential Diagnosis</xref>). Note: The genes included and the methods used in multi-gene panels vary by laboratory and over time. </p>
          <table-wrap id="milroy.T.summary_of_molecular_genetic_te" position="anchor" orientation="portrait">
            <label>Table 1.</label>
            <caption>
              <p>Summary of Molecular Genetic Testing Used in Milroy Disease</p>
            </caption>
            <table>
              <tbody>
                <tr>
                  <th id="hd_b_milroy.T.summary_of_molecular_genetic_te_1_1_1_1" align="left" valign="middle" rowspan="1" colspan="1">Gene&#x000a0;<sup>1</sup>
</th>
                  <th id="hd_b_milroy.T.summary_of_molecular_genetic_te_1_1_1_2" align="left" valign="middle" rowspan="1" colspan="1">Test Method</th>
                  <th id="hd_b_milroy.T.summary_of_molecular_genetic_te_1_1_1_3" align="left" valign="middle" rowspan="1" colspan="1">Proportion of Probands with a Pathogenic Variant Detectable by this Method</th>
                </tr>
                <tr>
                  <td headers="hd_b_milroy.T.summary_of_molecular_genetic_te_1_1_1_1" align="left" valign="middle" rowspan="1" colspan="1">
                    <italic toggle="yes">FLT4</italic>
                  </td>
                  <td headers="hd_b_milroy.T.summary_of_molecular_genetic_te_1_1_1_2" align="left" valign="middle" rowspan="1" colspan="1">Sequence analysis&#x000a0;<sup>2</sup></td>
                  <td headers="hd_b_milroy.T.summary_of_molecular_genetic_te_1_1_1_3" align="left" valign="middle" rowspan="1" colspan="1">Up to 75% in well-phenotyped cohorts&#x000a0;<sup>3</sup></td>
                </tr>
                <tr>
                  <td headers="hd_b_milroy.T.summary_of_molecular_genetic_te_1_1_1_1" align="left" valign="middle" rowspan="1" colspan="1">Unknown&#x000a0;<sup>4</sup></td>
                  <td headers="hd_b_milroy.T.summary_of_molecular_genetic_te_1_1_1_2" align="left" valign="middle" rowspan="1" colspan="1">NA</td>
                  <td headers="hd_b_milroy.T.summary_of_molecular_genetic_te_1_1_1_3" align="left" valign="middle" rowspan="1" colspan="1">NA</td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn id="milroy.TF.1">
                <label>1.</label>
                <p>See <related-object source-id="gene" document-id="milroy" object-id="milroy.molgen.TA">Table A. Genes and Databases</related-object> for chromosome locus and protein. See <xref ref-type="sec" rid="milroy.Molecular_Genetics">Molecular Genetics</xref> for information on allelic variants. </p>
              </fn>
              <fn id="milroy.TF.1.1">
                <label>2.</label>
                <p>Sequence analysis detects variants that are benign, likely benign, of unknown significance, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exonic or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click <related-object link-type="booklink" source-id="gene" document-id="app2" document-type="appendix">here</related-object>.</p>
              </fn>
              <fn id="milroy.TF.1.2">
                <label>3.</label>
                <p><xref ref-type="bibr" rid="milroy.REF.connell.2009.625">Connell et al [2009]</xref> suggest that a pathogenic variant is detected in 75% of those clearly affected and with a positive family history and in 68% of those with typical Milroy features but without a family history. </p>
              </fn>
              <fn id="milroy.TF.1.3">
                <label>4.</label>
                <p>No other loci have been identified, but reports suggest that Milroy disease is genetically heterogeneous [<xref ref-type="bibr" rid="milroy.REF.holberg.2001.303">Holberg et al 2001</xref>, <xref ref-type="bibr" rid="milroy.REF.evans.2003.697">Evans et al 2003</xref>]. Even when the individual has a clear clinical diagnosis, an <italic toggle="yes">FLT4</italic> pathogenic variant is found in only 75% of affected individuals, suggesting that other genes may be involved [<xref ref-type="bibr" rid="milroy.REF.connell.2009.625">Connell et al 2009</xref>]. Rare cases may be caused by pathogenic variants in <italic toggle="yes">VEGFC</italic> [<xref ref-type="bibr" rid="milroy.REF.gordon.2013a.956">Gordon et al 2013a</xref>]. </p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
        </sec>
      </sec>
      <sec id="milroy.Clinical_Description">
        <title>Clinical Characteristics</title>
        <sec id="milroy.Natural_History">
          <title>Clinical Description</title>
          <p>The most common finding in Milroy disease is lower-limb lymphedema. The edema is usually present from (or before) birth. In neonates the swelling tends to affect primarily the dorsum of the feet. Anecdotal evidence suggests that on rare occasions it develops later in life. </p>
          <p>The amount of edema varies both within and among families. Swelling is often bilateral, but can be asymmetric. </p>
          <p>The degree of edema sometimes progresses but in some instances can improve, particularly in early years. </p>
          <p>Other features sometimes associated with Milroy disease include:</p>
          <list list-type="bullet">
            <list-item>
              <p>Hydrocele (37% of males) </p>
            </list-item>
            <list-item>
              <p>Prominent veins (23%) </p>
            </list-item>
            <list-item>
              <p>Upslanting toenails (14%) </p>
            </list-item>
            <list-item>
              <p>Papillomatosis (10%) </p>
            </list-item>
            <list-item>
              <p>Urethral abnormalities in males (4%) </p>
            </list-item>
          </list>
          <p>Cellulitis occurs in approximately 20% of affected individuals, with infection significantly more likely in males than females [<xref ref-type="bibr" rid="milroy.REF.brice.2005.98">Brice et al 2005</xref>]. Cellulitis can damage the existing lymphatic vessels, resulting in an increase in the degree of swelling. </p>
          <p>Rarely, prenatal pleural effusion and hydrops fetalis have been reported [<xref ref-type="bibr" rid="milroy.REF.danielspiegel.2005.1015">Daniel-Spiegel et al 2005</xref>], but in general Milroy disease is not associated with more widespread lymphatic abnormalities. </p>
        </sec>
        <sec id="milroy.GenotypePhenotype_Correlations">
          <title>Genotype-Phenotype Correlations</title>
          <p>No genotype-phenotype correlation has been reported.</p>
          <p>Intra- and interfamilial variation in the phenotype is wide. </p>
        </sec>
        <sec id="milroy.Penetrance">
          <title>Penetrance</title>
          <p>Approximately 85%-90% of individuals who have a pathogenic variant in <italic toggle="yes">FLT4</italic> develop lower-limb lymphedema by age three years; conversely, 10%-15% of individuals with an <italic toggle="yes">FLT4</italic> pathogenic variant are clinically unaffected. </p>
        </sec>
        <sec id="milroy.Anticipation">
          <title>Anticipation</title>
          <p>Anticipation has not been observed.</p>
        </sec>
        <sec id="milroy.Nomenclature">
          <title>Nomenclature</title>
          <p>Milroy disease is named after William Milroy, who described 97 members of a family, of whom 26 had leg edema [<xref ref-type="bibr" rid="milroy.REF.milroy.1892.505">Milroy 1892</xref>]. In the family described by Milroy, the edema was painless, non-progressive, and confined to the lower limbs. </p>
          <p>Hereditary lymphedema of the legs was also described by <xref ref-type="bibr" rid="milroy.REF.nonne.1891.1">Nonne [1891]</xref>; hence, the term Nonne-Milroy disease has been used in the past.</p>
        </sec>
        <sec id="milroy.Prevalence">
          <title>Prevalence</title>
          <p>The prevalence of Milroy disease is not known but it appears to be one of the more common causes of primary lymphedema and occurs in all ethnic groups.</p>
        </sec>
      </sec>
      <sec id="milroy.Genetically_Related_Allelic_Disor">
        <title>Genetically Related (Allelic) Disorders</title>
        <p>No phenotypes other than those discussed in this <italic toggle="yes">GeneReview</italic> are known to be associated with mutation of <italic toggle="yes">FLT4</italic>. </p>
      </sec>
      <sec id="milroy.Differential_Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Milroy disease is suspected in individuals with 'woody' swelling of the dorsum of the feet with few associated features. Family history, if present, is consistent with autosomal dominant inheritance. </p>
        <p>A list of differential diagnoses can be found in <xref ref-type="bibr" rid="milroy.REF.connell.2013.303">Connell et al [2013]</xref>.</p>
        <p><bold>Microcephaly with or without chorioretinopathy, lymphedema, or mental retardation (MCLMR)</bold> (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/152950">152950</ext-link>). This autosomal dominant condition is caused by mutation of <italic toggle="yes">KIF11</italic>. The edema seen in individuals with a pathogenic variant in <italic toggle="yes">KIF11</italic> is indistinguishable from that associated with <italic toggle="yes">FLT4</italic> pathogenic variants. Features associated with <italic toggle="yes">KIF11</italic> pathogenic variants (and not seen in Milroy disease) include microcephaly, chorioretinopathy, and (in most individuals) learning difficulties. However, the pattern on lymphoscintigraphy in affected individuals is identical for the two disorders [<xref ref-type="bibr" rid="milroy.REF.ostergaard.2012.356">Ostergaard et al 2012</xref>, <xref ref-type="bibr" rid="milroy.REF.jones.2014.881">Jones et al 2014</xref>].</p>
        <p><bold><italic toggle="yes">VEGFC</italic>-related lymphoedema.</bold> Two families with a phenotype resembling Milroy disease have been shown to have pathogenic variants in <italic toggle="yes">VEGFC</italic>. Clinically, it is not possible to distinguish these individuals from those with <italic toggle="yes">FLT4</italic> pathogenic variants and testing of <italic toggle="yes">VEGFC</italic> should be considered if <italic toggle="yes">FLT4</italic> testing is negative. The pattern on lymphoscintigraphy in individuals with <italic toggle="yes">VEGFC</italic> pathogenic variants is different from that in patients with Milroy disease [<xref ref-type="bibr" rid="milroy.REF.gordon.2013a.956">Gordon et al 2013a</xref>].</p>
        <p>Other disorders in the differential diagnosis may be distinguished by age of onset.</p>
        <p><bold>Turner syndrome</bold> is the combination of a characteristic phenotype in females who have one normal X chromosome and either (1) absence of the second sex chromosome (X or Y) with or without mosaicism or (2) partial deletion of the X chromosome. The Turner syndrome phenotype includes short stature, stature disproportion, primary amenorrhea, neck webbing, congenital lymphedema of the hands and feet, high-arched palate, short metacarpals, scoliosis, Madelung deformity, hearing difficulties, cardiac and renal anomalies, hypothyroidism, and glucose intolerance [<xref ref-type="bibr" rid="milroy.REF.batch.2002.465">Batch 2002</xref>, <xref ref-type="bibr" rid="milroy.REF.sybert.2004.1227">Sybert &#x00026; McCauley 2004</xref>]. Lymphedema in this syndrome affects the extremities and often improves over time. Turner syndrome occurs in 1:2500 to 1:3000 live female births [<xref ref-type="bibr" rid="milroy.REF.sybert.2004.1227">Sybert &#x00026; McCauley 2004</xref>] and should always be considered in a female with congenital lymphedema particularly if hands and feet are affected </p>
        <p><related-object link-type="booklink" source-id="gene" document-id="noonan" document-type="chapter"><bold>Noonan syndrome</bold></related-object> is characterized by short stature, congenital heart defect, and developmental delay of variable degree. Other findings can include broad or webbed neck, unusual chest shape with superior pectus carinatum and inferior pectus excavatum, cryptorchidism, and characteristic facies. Varied coagulation defects and lymphatic dysplasias are observed with onset at birth or in childhood. Pulmonary valve stenosis, often with dysplasia, is the most common heart defect and is found in 20%-50% of individuals. Hypertrophic cardiomyopathy, found in 20%-30% of individuals, may be present at birth or appear in infancy or childhood. Pathogenic variants in <italic toggle="yes">PTPN11</italic> are observed in 50% of affected individuals, <italic toggle="yes">SOS1</italic> in approximately 13%, <italic toggle="yes">RAF1</italic> in 3%-17%, and <italic toggle="yes">KRAS</italic> in fewer than 5%. Other genes in which pathogenic variants have been reported to cause Noonan syndrome in fewer than 1% of cases include <italic toggle="yes">NRAS</italic>, <italic toggle="yes">BRAF</italic>, and <italic toggle="yes">MAP2K1</italic>. Inheritance is autosomal dominant. People with Noonan syndrome may present with congenital lymphedema of the feet and legs. They may also present later with lower-limb and genital edema, chylous reflux, intestinal lymphangiectasia, and/or chylothoraces.</p>
        <p><bold>Hypotrichosis-lymphedema-telangiectasia syndrome</bold> (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/607823">607823</ext-link>) is the association of childhood-onset lymphedema in the lower limbs, loss of hair, and telangiectasia, particularly on the palms. Inheritance is either autosomal dominant or autosomal recessive. Pathogenic variants in <italic toggle="yes">SOX18</italic> are causative [<xref ref-type="bibr" rid="milroy.REF.irrthum.2003.1470">Irrthum et al 2003</xref>]. </p>
        <p><related-object link-type="booklink" source-id="gene" document-id="lds" document-type="chapter"><bold>Lymphedema-distichiasis syndrome</bold></related-object> is characterized by lower-limb lymphedema and distichiasis. Lymphedema typically appears in late childhood or puberty, is confined to the lower limbs, and is often asymmetric; severity varies within families. Males develop edema at an earlier age and have more problems with cellulitis than females. Distichiasis, which may be present at birth and is observed in 94% of affected individuals, describes the presence of aberrant eyelashes arising from the Meibomian glands ranging from a full set of extra eyelashes to a single hair. About 75% of affected individuals have ocular findings resulting from the aberrant eyelashes including corneal irritation, recurrent conjunctivitis, and photophobia; other common findings include early-onset varicose veins (50%), congenital heart disease (7%), and ptosis (30%). About 25% of individuals are asymptomatic. <italic toggle="yes">FOXC2</italic> is the only gene known to be associated with lymphedema-distichiasis syndrome. Inheritance is autosomal dominant. </p>
        <p><bold>Meige disease</bold> (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/153200">153200</ext-link>) presents with pubertal-onset lymphedema. No other features appear to be associated. Women are more commonly affected than men. No genes have been identified as yet. Inheritance appears to be autosomal dominant with reduced penetrance. </p>
        <p><bold>Lymphedema with yellow nails</bold> (yellow nail syndrome, YNS) (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/153300">153300</ext-link>) often presents after age 50 years. The nails in YNS are very slow growing, with transverse over-curvature and hardening of the nail plate. The nail changes are different from the typically discolored nails that are often associated with chronic lymphedema of any cause. Inheritance is said to be autosomal dominant; however, most cases are not associated with a family history [<xref ref-type="bibr" rid="milroy.REF.hoque.2007.1230">Hoque et al 2007</xref>, <xref ref-type="bibr" rid="milroy.REF.maldonado.2008.375">Maldonado et al 2008</xref>].</p>
      </sec>
      <sec id="milroy.Management">
        <title>Management</title>
        <sec id="milroy.Evaluations_Following_Initial_Dia">
          <title>Evaluations Following Initial Diagnosis </title>
          <p>To establish the extent of disease and needs in an individual diagnosed with Milroy disease, the following evaluations are recommended:</p>
          <list list-type="bullet">
            <list-item>
              <p>Medical genetics consultation</p>
            </list-item>
            <list-item>
              <p>Referral to a lymphedema therapist</p>
            </list-item>
            <list-item>
              <p>Lymphoscintigraphy</p>
            </list-item>
          </list>
        </sec>
        <sec id="milroy.Treatment_of_Manifestations">
          <title>Treatment of Manifestations</title>
          <p>Guidance by a lymphedema therapist regarding management of edema (e.g., fitting stockings, massage) is important. Although the edema cannot be cured, some improvement is usually possible with the use of properly fitted compression hosiery and/or bandaging and well fitting, supportive shoes. Toe gloves may be of benefit and good skin care is essential. Such treatment measures may improve the cosmetic appearance of the limb, decrease the size of the limb, and reduce the risk of complications.</p>
        </sec>
        <sec id="milroy.Prevention_of_Secondary_Complicat">
          <title>Prevention of Secondary Complications </title>
          <p>Secondary cellulitis is prevented through the following measures:</p>
          <list list-type="bullet">
            <list-item>
              <p>Prevention of foot infections, particularly athlete's foot/infected eczema </p>
            </list-item>
            <list-item>
              <p>Prompt treatment for early cellulitis with appropriate antibiotics. It may be necessary to give the first few doses intravenously. </p>
            </list-item>
            <list-item>
              <p>Prophylactic antibiotics in recurrent cases (e.g., penicillin V 500 mg daily) </p>
            </list-item>
          </list>
        </sec>
        <sec id="milroy.Surveillance">
          <title>Surveillance </title>
          <p>Routine follow up in a clinic specializing in the care of lymphedema is appropriate.</p>
        </sec>
        <sec id="milroy.AgentsCircumstances_to_Avoid">
          <title>Agents/Circumstances to Avoid</title>
          <p>The following should be avoided:</p>
          <list list-type="bullet">
            <list-item>
              <p>Wounds to the swollen limbs, because of their reduced resistance to infection </p>
            </list-item>
            <list-item>
              <p>Long periods of immobility with the legs in a dependent position (e.g., on a long airplane flight)</p>
            </list-item>
            <list-item>
              <p>Medications, particularly calcium channel-blocking drugs, that can cause increased leg swelling in some individuals </p>
            </list-item>
          </list>
        </sec>
        <sec id="milroy.Evaluation_of_Relatives_at_Risk">
          <title>Evaluation of Relatives at Risk</title>
          <p>If the <italic toggle="yes">FLT4</italic> pathogenic variant in a family is known, molecular genetic testing of at-risk relatives ensures identification of those who will benefit from treatment early in the disease course. </p>
          <p>If the pathogenic variant in a family is not known, evaluation of relatives at risk by physical examination is appropriate in order to identify those who will benefit from treatment early in the course of the disease. The use of properly fitted compression hosiery and advice to reduce the risk of cellulitis of the legs and feet can be beneficial. </p>
          <p>See <xref ref-type="sec" rid="milroy.Related_Genetic_Counseling_Issues">Genetic Counseling</xref> for issues related to testing of at-risk relatives for genetic counseling purposes.</p>
        </sec>
        <sec id="milroy.Pregnancy_Management">
          <title>Pregnancy Management </title>
          <p>Ultrasound scanning during pregnancy may indicate if a fetus is affected if swelling of the dorsum of the feet is noted in the second or third trimester. The fetus may have mild pleural effusions which frequently resolve before birth [S Mansour, personal communication]. Very rarely, the fetus may present with hydrops fetalis. If the mother is affected by Milroy disease there may be an increase in swelling during the pregnancy.</p>
        </sec>
        <sec id="milroy.Therapies_Under_Investigation">
          <title>Therapies Under Investigation</title>
          <p>Attempts at over-expressing VEGF-C, the ligand for <italic toggle="yes">FLT4</italic>, have been successful in producing functional lymphatics in mice [<xref ref-type="bibr" rid="milroy.REF.karkkainen.2000b.12677">Karkkainen et al 2000b</xref>]. This is now in clinical trial in Finland for human breast cancer-related lymphedema.</p>
          <p>Search <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://clinicaltrials.gov/">ClinicalTrials.gov</ext-link> for access to information on clinical studies for a wide range of diseases and conditions.</p>
        </sec>
        <sec id="milroy.Other">
          <title>Other</title>
          <p>Treatment with diuretics is of no proven benefit.</p>
        </sec>
      </sec>
      <sec id="milroy.Genetic_Counseling">
        <title>Genetic Counseling</title>
        <sec id="milroy.Mode_of_Inheritance">
          <title>Mode of Inheritance</title>
          <p>Milroy disease is inherited in an autosomal dominant manner.</p>
        </sec>
        <sec id="milroy.Risk_to_Family_Members">
          <title>Risk to Family Members</title>
          <p><bold>Parents of a proband</bold>
</p>
          <list list-type="bullet">
            <list-item>
              <p>Most individuals diagnosed with Milroy disease have an affected parent. </p>
            </list-item>
            <list-item>
              <p>A proband with Milroy disease may have the disorder as the result of <italic toggle="yes">de novo FLT4</italic> mutation. The proportion of cases caused by <italic toggle="yes">de novo</italic> mutation is not presently known, as a clinical delineator for Milroy disease has, in the past, included a family history of the disorder. Of the 15 pathogenic variants discovered in the authors' laboratory to date (7 of these unpublished data), three represent <italic toggle="yes">de novo</italic> mutations [<xref ref-type="bibr" rid="milroy.REF.carver.2007.187">Carver et al 2007</xref>]. Previously, one <italic toggle="yes">de novo</italic> mutation was reported [<xref ref-type="bibr" rid="milroy.REF.ghalamkarpour.2006.330">Ghalamkarpour et al 2006</xref>]. </p>
            </list-item>
            <list-item>
              <p>If the pathogenic variant found in the proband cannot be detected in the DNA of either parent, two possible explanations are germline mosaicism in a parent or a <italic toggle="yes">de novo</italic> mutation in the proband. Germline mosaicism has been observed [Author, personal communication] but remains uncommon. </p>
            </list-item>
          </list>
          <p>Note: Although most individuals diagnosed with Milroy disease have an affected parent, the family history may appear to be negative because of failure to recognize the disorder in family members as a result of variable expression or reduced penetrance. Somatic mosaicism for pathogenic variants in <italic toggle="yes">FLT4</italic> is rare but has occurred [Author, personal communication].</p>
          <p><bold>Sibs of a proband</bold>
</p>
          <list list-type="bullet">
            <list-item>
              <p>The risk to the sibs of the proband depends on the genetic status of the proband's parents. </p>
            </list-item>
            <list-item>
              <p>If a parent of the proband is affected or has an <italic toggle="yes">FLT4</italic> pathogenic variant, the risk to the sibs is 50%. </p>
            </list-item>
            <list-item>
              <p>If the pathogenic variant found in the proband cannot be detected in the DNA of either parent, the risk to sibs is low but greater than that of the general population because of the possibility of germline mosaicism. </p>
            </list-item>
            <list-item>
              <p>When the parents are clinically unaffected, the risk to the sibs of a proband appears to be low, but greater than that of the general population because of the possibilities of non-penetrance and germline mosaicism. </p>
            </list-item>
          </list>
          <p><bold>Offspring of a proband.</bold> Each child of an individual with Milroy disease has a 50% chance of inheriting the <italic toggle="yes">FLT4</italic> pathogenic variant. </p>
          <p><bold>Other family members of a proband.</bold> The risk to other family members depends on the status of the proband's parents. If a parent is affected, his or her family members are at risk. </p>
        </sec>
        <sec id="milroy.Related_Genetic_Counseling_Issues">
          <title>Related Genetic Counseling Issues</title>
          <p>See Management, <xref ref-type="sec" rid="milroy.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</xref> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p>
          <p><bold>Predictive testing</bold> for at-risk asymptomatic adult family members requires prior identification of the <italic toggle="yes">FLT4</italic> pathogenic variant in the family. </p>
          <p><bold>Considerations in families with an apparent <italic toggle="yes">de novo</italic> mutation.</bold> When neither parent of a proband with an autosomal dominant condition has the pathogenic variant or clinical evidence of the disorder, it is likely that the proband has a <italic toggle="yes">de novo</italic> mutation. However, possible non-medical explanations including alternate paternity or maternity (e.g., with assisted reproduction) or undisclosed adoption could also be explored. </p>
          <p>
            <bold>Family planning</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The optimal time for determination of genetic risk and discussion of the availability of prenatal testing is before pregnancy. </p>
            </list-item>
            <list-item>
              <p>It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected or at risk.</p>
            </list-item>
          </list>
          <p><bold>DNA banking</bold> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals. </p>
        </sec>
        <sec id="milroy.Prenatal_Testing">
          <title>Prenatal Testing</title>
          <p><bold>Molecular genetic testing.</bold> If the <italic toggle="yes">FLT4</italic> pathogenic variant has been identified in an affected family member, prenatal testing for pregnancies at increased risk may be available from a clinical laboratory that offers either testing of this gene or custom prenatal testing. </p>
          <p>Requests for prenatal testing for conditions which (like Milroy disease) do not affect intellect and have some treatment available are not common. Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. Although most centers would consider decisions about prenatal testing to be the choice of the parents, discussion of these issues is appropriate. </p>
          <p><bold>Ultrasound examination.</bold> Ultrasonography during pregnancy may detect swelling of the dorsum of the feet, mild pleural effusions which often resolve, and (very rarely) more extensive edematous states (hydrops fetalis) in an affected fetus [<xref ref-type="bibr" rid="milroy.REF.franceschini.2001.182">Franceschini et al 2001</xref>, <xref ref-type="bibr" rid="milroy.REF.makhoul.2002.823">Makhoul et al 2002</xref>, <xref ref-type="bibr" rid="milroy.REF.danielspiegel.2005.1015">Daniel-Spiegel et al 2005</xref>]. </p>
          <p><bold>Preimplantation genetic diagnosis (PGD)</bold> may be an option for some families in which the <italic toggle="yes">FLT4</italic> pathogenic variant has been identified. </p>
        </sec>
      </sec>
      <sec id="milroy.Resources">
        <title>Resources</title>
      </sec>
      <sec id="milroy.Molecular_Genetics">
        <title>Molecular Genetics</title>
        <p><bold>Gene structure.</bold> The normal gene is about 45 kb in length; it has 31 exons and two mRNAs of 4.5 kb and 5.8 kb, the latter being the more predominant species. For a detailed summary of gene and protein information, see <related-object source-id="gene" document-id="milroy" object-id="milroy.molgen.TA">Table A</related-object>, <bold>Gene</bold>.</p>
        <p><bold>Benign allelic variants.</bold> Normal variants include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>p.Pro641Ser, p.Asn199Asp, p.Thr494Ala, p.Gln890His, p.Pro954Ser, p.Pro1008Leu, p.Arg1146His, p.Arg1342Leu </p>
          </list-item>
          <list-item>
            <p>c.507G&#x0003e;T, c.3198T&#x0003e;C (silent); 17 intronic polymorphisms are detailed in <xref ref-type="bibr" rid="milroy.REF.iljin.2001.1028">Iljin et al [2001]</xref>. </p>
          </list-item>
        </list>
        <p><bold>Pathogenic allelic variants.</bold> All pathogenic variants identified to date have been in exons encoding tyrosine kinase domains. Identification of pathogenic variants only in these exons may in part be the result of a bias in ascertainment; however, <xref ref-type="bibr" rid="milroy.REF.connell.2009.625">Connell et al [2009]</xref> screened all exons of <italic toggle="yes">FLT4</italic> and did not find any pathogenic variants outside the tyrosine kinase domains. See <xref ref-type="bibr" rid="milroy.REF.gordon.2013b.23">Gordon et al [2013b]</xref> for discussion of variants reported in the literature. </p>
        <p><bold>Normal gene product.</bold> The normal gene product, VEGFR-3 (vascular endothelial growth factor receptor 3), is a dimeric receptor for the ligands VEGFC and VEGFD. VEGFR-3 is a lymphatic endothelial cell-specific receptor tyrosine kinase. </p>
        <p><bold>Abnormal gene product.</bold> The abnormal gene products are either mutant/mutant type homodimers showing no tyrosine kinase activity or mutant/wild type heterodimers showing some TK activity [<xref ref-type="bibr" rid="milroy.REF.irrthum.2000.295">Irrthum et al 2000</xref>, <xref ref-type="bibr" rid="milroy.REF.karkkainen.2000a.153">Karkkainen et al 2000a</xref>]. However, the only pathogenic variants to have been tested in this way are p.Gly857Arg, p.His1035Arg, p.Arg1041Pro, p.Leu1044Pro, and p.Pro1114Leu. </p>
      </sec>
      <sec id="milroy.References">
        <title>References</title>
        <sec id="milroy.Literature_Cited">
          <title>Literature Cited</title>
          <ref-list id="milroy.Literature_Cited.reflist0">
            <ref id="milroy.REF.batch.2002.465">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Batch</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <article-title>Turner syndrome in childhood and adolescence.</article-title>
                <source>Best Pract Res Clin Endocrinol Metab</source>
                <year>2002</year>
                <volume>16</volume>
                <fpage>465</fpage>
                <lpage>82</lpage>
                <pub-id pub-id-type="pmid">12464229</pub-id>
              </element-citation>
            </ref>
            <ref id="milroy.REF.brice.2005.98">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Brice</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Child</surname>
                    <given-names>AH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Evans</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bell</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mansour</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Burnand</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sarfarazi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jeffery</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mortimer</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <article-title>Milroy disease and the VEGFR-3 mutation phenotype.</article-title>
                <source>J Med Genet</source>
                <year>2005</year>
                <volume>42</volume>
                <fpage>98</fpage>
                <lpage>102</lpage>
                <pub-id pub-id-type="pmid">15689446</pub-id>
              </element-citation>
            </ref>
            <ref id="milroy.REF.carver.2007.187">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Carver</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brice</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mansour</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ostergaard</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mortimer</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jeffery</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <article-title>Three children with Milroy disease and de novo mutations in VEGFR3.</article-title>
                <source>Clin Genet</source>
                <year>2007</year>
                <volume>71</volume>
                <fpage>187</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">17250670</pub-id>
              </element-citation>
            </ref>
            <ref id="milroy.REF.connell.2013.303">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Connell</surname>
                    <given-names>FC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gordon</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brice</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Keeley</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jeffery</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mortimer</surname>
                    <given-names>PS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mansour</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ostergaard</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <article-title>The classification and diagnostic algorithm for primary lymphatic dysplasia: an update from 2010 to include molecular findings.</article-title>
                <source>Clin Genet.</source>
                <year>2013</year>
                <volume>84</volume>
                <fpage>303</fpage>
                <lpage>14</lpage>
                <pub-id pub-id-type="pmid">23621851</pub-id>
              </element-citation>
            </ref>
            <ref id="milroy.REF.connell.2009.625">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Connell</surname>
                    <given-names>FC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ostergaard</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Carver</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brice</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Williams</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mansour</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mortimer</surname>
                    <given-names>PS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jeffery</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <publisher-name>Lymphoedema Consortium</publisher-name>
                <article-title>Analysis of the coding regions of VEGFR3 and VEGFC in Milroy disease and other primary lymphoedemas.</article-title>
                <source>Hum Genet</source>
                <year>2009</year>
                <volume>124</volume>
                <fpage>625</fpage>
                <lpage>31</lpage>
                <pub-id pub-id-type="pmid">19002718</pub-id>
              </element-citation>
            </ref>
            <ref id="milroy.REF.danielspiegel.2005.1015">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Daniel-Spiegel</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ghalamkarpour</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Spiegel</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weiner</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vikkula</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shalev</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shalev</surname>
                    <given-names>SA</given-names>
                  </name>
                </person-group>
                <article-title>Hydrops fetalis: an unusual prenatal presentation of hereditary congenital lymphedema.</article-title>
                <source>Prenat Diagn</source>
                <year>2005</year>
                <volume>25</volume>
                <fpage>1015</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">16231305</pub-id>
              </element-citation>
            </ref>
            <ref id="milroy.REF.evans.2003.697">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Evans</surname>
                    <given-names>AL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bell</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brice</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Comeglio</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lipede</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jeffery</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mortimer</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sarfarazi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Child</surname>
                    <given-names>AH</given-names>
                  </name>
                </person-group>
                <article-title>Identification of eight novel VEGFR-3 mutations in families with primary congenital lymphoedema.</article-title>
                <source>J Med Genet</source>
                <year>2003</year>
                <volume>40</volume>
                <fpage>697</fpage>
                <lpage>703</lpage>
                <pub-id pub-id-type="pmid">12960217</pub-id>
              </element-citation>
            </ref>
            <ref id="milroy.REF.ferrell.1998.2073">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ferrell</surname>
                    <given-names>RE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Levinson</surname>
                    <given-names>KL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Esman</surname>
                    <given-names>JH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kimak</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lawrence</surname>
                    <given-names>EC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barmada</surname>
                    <given-names>MM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Finegold</surname>
                    <given-names>DN</given-names>
                  </name>
                </person-group>
                <article-title>Hereditary lymphedema: evidence for linkage and genetic heterogeneity.</article-title>
                <source>Hum Mol Genet</source>
                <year>1998</year>
                <volume>7</volume>
                <fpage>2073</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">9817924</pub-id>
              </element-citation>
            </ref>
            <ref id="milroy.REF.franceschini.2001.182">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Franceschini</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Licata</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rapello</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Guala</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Di Cara</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Franceschini</surname>
                    <given-names>D</given-names>
                  </name>
                </person-group>
                <article-title>Prenatal diagnosis of Nonne-Milroy lymphedema.</article-title>
                <source>Ultrasound Obstet Gynecol</source>
                <year>2001</year>
                <volume>18</volume>
                <fpage>182</fpage>
                <lpage>3</lpage>
                <pub-id pub-id-type="pmid">11547763</pub-id>
              </element-citation>
            </ref>
            <ref id="milroy.REF.ghalamkarpour.2006.330">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ghalamkarpour</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Morlot</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Raas-Rothschild</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Utkus</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mulliken</surname>
                    <given-names>JB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boon</surname>
                    <given-names>LM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vikkula</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <article-title>Hereditary lymphedema type I associated with VEGFR3 mutation: the first de novo case and atypical presentations.</article-title>
                <source>Clin Genet</source>
                <year>2006</year>
                <volume>70</volume>
                <fpage>330</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">16965327</pub-id>
              </element-citation>
            </ref>
            <ref id="milroy.REF.gordon.2013a.956">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gordon</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schulte</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brice</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Simpson</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roukens</surname>
                    <given-names>MG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Impel</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Connell</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kalidas</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jeffery</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mortimer</surname>
                    <given-names>PS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mansour</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schulte-Merker</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ostergaard</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <article-title>Mutation in vascular endothelial growth factor-C, a ligand for vascular endothelial growth factor receptor-3, is associated with autosomal dominant Milroy-like primary lymphedema.</article-title>
                <source>Circ Res.</source>
                <year>2013a</year>
                <volume>112</volume>
                <fpage>956</fpage>
                <lpage>60</lpage>
                <pub-id pub-id-type="pmid">23410910</pub-id>
              </element-citation>
            </ref>
            <ref id="milroy.REF.gordon.2013b.23">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gordon</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Spiden</surname>
                    <given-names>SL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Connell</surname>
                    <given-names>FC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brice</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cottrell</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Short</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Taylor</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jeffery</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mortimer</surname>
                    <given-names>PS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mansour</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ostergaard</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <article-title>FLT4/VEGFR3 and Milroy disease: novel mutations, a review of published variants and database update.</article-title>
                <source>Hum Mutat.</source>
                <year>2013b</year>
                <volume>34</volume>
                <fpage>23</fpage>
                <lpage>31</lpage>
                <pub-id pub-id-type="pmid">23074044</pub-id>
              </element-citation>
            </ref>
            <ref id="milroy.REF.holberg.2001.303">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Holberg</surname>
                    <given-names>CJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Erickson</surname>
                    <given-names>RP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bernas</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Witte</surname>
                    <given-names>MH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fultz</surname>
                    <given-names>KE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Andrade</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Witte</surname>
                    <given-names>CL</given-names>
                  </name>
                </person-group>
                <article-title>Segregation analyses and a genome-wide linkage search confirm genetic heterogeneity and suggest oligogenic inheritance in some Milroy congenital primary lymphedema families.</article-title>
                <source>Am J Med Genet</source>
                <year>2001</year>
                <volume>98</volume>
                <fpage>303</fpage>
                <lpage>12</lpage>
                <pub-id pub-id-type="pmid">11170072</pub-id>
              </element-citation>
            </ref>
            <ref id="milroy.REF.hoque.2007.1230">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hoque</surname>
                    <given-names>SR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mansour</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mortimer</surname>
                    <given-names>PS</given-names>
                  </name>
                </person-group>
                <article-title>Yellow nail syndrome: not a genetic disorder? Eleven new cases and a review of the literature.</article-title>
                <source>Br J Dermatol</source>
                <year>2007</year>
                <volume>156</volume>
                <fpage>1230</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">17459037</pub-id>
              </element-citation>
            </ref>
            <ref id="milroy.REF.iljin.2001.1028">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Iljin</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Karkkainen</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lawrence</surname>
                    <given-names>EC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kimak</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Uutela</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Taipale</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pajusola</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Alhonen</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Halmekyto</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Finegold</surname>
                    <given-names>DN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ferrell</surname>
                    <given-names>RE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Alitalo</surname>
                    <given-names>K</given-names>
                  </name>
                </person-group>
                <article-title>VEGFR3 gene structure, regulatory region, and sequence polymorphisms.</article-title>
                <source>FASEB J</source>
                <year>2001</year>
                <volume>15</volume>
                <fpage>1028</fpage>
                <lpage>36</lpage>
                <pub-id pub-id-type="pmid">11292664</pub-id>
              </element-citation>
            </ref>
            <ref id="milroy.REF.irrthum.2003.1470">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Irrthum</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Devriendt</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chitayat</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Matthijs</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Glade</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Steijlen</surname>
                    <given-names>PM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fryns</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Van Steensel</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vikkula</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <article-title>Mutations in the transcription factor gene SOX18 underlie recessive and dominant forms of hypotrichosis-lymphedema-telangiectasia.</article-title>
                <source>Am J Hum Genet</source>
                <year>2003</year>
                <volume>72</volume>
                <fpage>1470</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">12740761</pub-id>
              </element-citation>
            </ref>
            <ref id="milroy.REF.irrthum.2000.295">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Irrthum</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Karkkainen</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Devriendt</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Alitalo</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vikkula</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <article-title>Congenital hereditary lymphedema caused by a mutation that inactivates VEGFR3 tyrosine kinase.</article-title>
                <source>Am J Hum Genet</source>
                <year>2000</year>
                <volume>67</volume>
                <fpage>295</fpage>
                <lpage>301</lpage>
                <pub-id pub-id-type="pmid">10856194</pub-id>
              </element-citation>
            </ref>
            <ref id="milroy.REF.jones.2014.881">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Jones</surname>
                    <given-names>GE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ostergaard</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moore</surname>
                    <given-names>AT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Connell</surname>
                    <given-names>FC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Williams</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Quarrell</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brady</surname>
                    <given-names>AF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Spier</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hazan</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moldovan</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wieczorek</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mikat</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Petit</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Coubes</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Saul</surname>
                    <given-names>RA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brice</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gordon</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jeffery</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mortimer</surname>
                    <given-names>PS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vasudevan</surname>
                    <given-names>PC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mansour</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <article-title>Microcephaly with or without chorioretinopathy, lymphoedema, or mental retardation (MCLMR): review of phenotype associated with KIF11 mutations.</article-title>
                <source>Eur J Hum Genet.</source>
                <year>2014</year>
                <volume>22</volume>
                <fpage>881</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">24281367</pub-id>
              </element-citation>
            </ref>
            <ref id="milroy.REF.karkkainen.2000a.153">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Karkkainen</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ferrell</surname>
                    <given-names>RE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lawrence</surname>
                    <given-names>EC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kimak</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Levinson</surname>
                    <given-names>KL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McTigue</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Alitalo</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Finegold</surname>
                    <given-names>DN</given-names>
                  </name>
                </person-group>
                <article-title>Missense mutations interfere with VEGFR-3 signalling in primary lymphoedema.</article-title>
                <source>Nat Genet</source>
                <year>2000a</year>
                <volume>25</volume>
                <fpage>153</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">10835628</pub-id>
              </element-citation>
            </ref>
            <ref id="milroy.REF.karkkainen.2000b.12677">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Karkkainen</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Saaristo</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jussila</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Karila</surname>
                    <given-names>KA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lawrence</surname>
                    <given-names>EC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pajusola</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bueler</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eichmann</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kauppinen</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kettunen</surname>
                    <given-names>MI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yla-Herttuala</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Finegold</surname>
                    <given-names>DN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ferrell</surname>
                    <given-names>RE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Alitalo</surname>
                    <given-names>K</given-names>
                  </name>
                </person-group>
                <article-title>A model for gene therapy of human hereditary lymphedema.</article-title>
                <source>Proc Natl Acad Sci U S A</source>
                <year>2000b</year>
                <volume>98</volume>
                <fpage>12677</fpage>
                <lpage>82</lpage>
              </element-citation>
            </ref>
            <ref id="milroy.REF.makhoul.2002.823">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Makhoul</surname>
                    <given-names>IR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sujov</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ghanem</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bronshtein</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <article-title>Prenatal diagnosis of Milroy's primary congenital lymphedema.</article-title>
                <source>Prenat Diagn</source>
                <year>2002</year>
                <volume>22</volume>
                <fpage>823</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">12224079</pub-id>
              </element-citation>
            </ref>
            <ref id="milroy.REF.maldonado.2008.375">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Maldonado</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tazelaar</surname>
                    <given-names>HD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wang</surname>
                    <given-names>CW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ryu</surname>
                    <given-names>JH</given-names>
                  </name>
                </person-group>
                <article-title>Yellow nail syndrome: analysis of 41 consecutive patients.</article-title>
                <source>Chest</source>
                <year>2008</year>
                <volume>134</volume>
                <fpage>375</fpage>
                <lpage>81</lpage>
                <pub-id pub-id-type="pmid">18403655</pub-id>
              </element-citation>
            </ref>
            <ref id="milroy.REF.milroy.1892.505">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Milroy</surname>
                    <given-names>WF</given-names>
                  </name>
                </person-group>
                <article-title>An undescribed variety of hereditary oedema.</article-title>
                <source>NY Med J.</source>
                <year>1892</year>
                <volume>56</volume>
                <fpage>505</fpage>
                <lpage>8</lpage>
              </element-citation>
            </ref>
            <ref id="milroy.REF.nonne.1891.1">
              <mixed-citation publication-type="book">Nonne M. Vier Falle von Elephantiasis congenita hereditaria. <italic toggle="yes">Archiv fur pathologische Anatomie und Physiologie und fur klinische Medicin.</italic> Berlin, Germany;1891:189-96. </mixed-citation>
            </ref>
            <ref id="milroy.REF.ostergaard.2012.356">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ostergaard</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Simpson</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mendola</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vasudevan</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Connell</surname>
                    <given-names>FC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Impel</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moore</surname>
                    <given-names>AT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Loeys</surname>
                    <given-names>BL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ghalamkarpour</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Onoufriadis</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Martinez-Corral</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Devery</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leroy</surname>
                    <given-names>JG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Laer</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Singer</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bialer</surname>
                    <given-names>MG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McEntagart</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Quarrell</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brice</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Trembath</surname>
                    <given-names>RC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schulte-Merker</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Makinen</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vikkula</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mortimer</surname>
                    <given-names>PS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mansour</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jeffery</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <article-title>Mutations in KIF11 cause autosomal-dominant microcephaly variably associated with congenital lymphedema and chorioretinopathy.</article-title>
                <source>Am J Hum Genet.</source>
                <year>2012</year>
                <volume>90</volume>
                <fpage>356</fpage>
                <lpage>62</lpage>
                <pub-id pub-id-type="pmid">22284827</pub-id>
              </element-citation>
            </ref>
            <ref id="milroy.REF.sybert.2004.1227">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sybert</surname>
                    <given-names>VP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McCauley</surname>
                    <given-names>E</given-names>
                  </name>
                </person-group>
                <article-title>Turner's syndrome.</article-title>
                <source>N Engl J Med</source>
                <year>2004</year>
                <volume>351</volume>
                <fpage>1227</fpage>
                <lpage>38</lpage>
                <pub-id pub-id-type="pmid">15371580</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
        <sec id="milroy.Suggested_Reading">
          <title>Suggested Reading </title>
          <ref-list id="milroy.Suggested_Reading.reflist0">
            <ref id="milroy.REF.meige.1898.341">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Meige</surname>
                    <given-names>H</given-names>
                  </name>
                </person-group>
                <article-title>Dystrophie oedemateuse hereditarie.</article-title>
                <source>Press Med</source>
                <year>1898</year>
                <volume>6</volume>
                <fpage>341</fpage>
                <lpage>3</lpage>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
      </sec>
      <sec id="milroy.Chapter_Notes">
        <title>Chapter Notes</title>
        <sec id="milroy.Author_History">
          <title>Author History</title>
          <p>Glen W Brice, RGN BSc (Hons) (2005-present)Fiona Connell, MBChB, MRCPCH, MD (2009-present)Steve Jeffery, PhD (2005-present)Sahar Mansour, FRCP (2005-present)Peter Mortimer, MD, FRCP (2005-present)Pia Ostergaard, PhD (2009-present)Carolyn Sholto-Douglas-Vernon, PhD; University of London (2005-2009)</p>
        </sec>
        <sec id="milroy.Revision_History">
          <title>Revision History</title>
          <list list-type="bullet">
            <list-item>
              <p>25 September 2014 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>23 July 2009 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>6 April 2007 (gb) Revision: sequence analysis and prenatal testing clinically available </p>
            </list-item>
            <list-item>
              <p>27 April 2006 (me) Review posted to live Web site </p>
            </list-item>
            <list-item>
              <p>19 July 2005 (gb) Original submission</p>
            </list-item>
          </list>
        </sec>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
